303 related articles for article (PubMed ID: 33037092)
1. Combination Strategies to Improve Targeted Radionuclide Therapy.
Chan TG; O'Neill E; Habjan C; Cornelissen B
J Nucl Med; 2020 Nov; 61(11):1544-1552. PubMed ID: 33037092
[TBL] [Abstract][Full Text] [Related]
2. Targeted radionuclide therapy in combined-modality regimens.
Gill MR; Falzone N; Du Y; Vallis KA
Lancet Oncol; 2017 Jul; 18(7):e414-e423. PubMed ID: 28677577
[TBL] [Abstract][Full Text] [Related]
3. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
[TBL] [Abstract][Full Text] [Related]
4. The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
Lundsten S; Spiegelberg D; Stenerlöw B; Nestor M
Int J Oncol; 2019 Dec; 55(6):1287-1295. PubMed ID: 31638190
[TBL] [Abstract][Full Text] [Related]
5. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.
Damiana TST; Dalm SU
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34067215
[TBL] [Abstract][Full Text] [Related]
8. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
9. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
Bellavia MC; Patel RB; Anderson CJ
J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapies and radiation therapy in non-small cell lung cancer].
Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
Kabakov AE; Kudriavtsev VA; Makarova IuM
Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
[TBL] [Abstract][Full Text] [Related]
15. Strategizing the clone wars: pharmacological control of cellular sensitivity to radiation.
Kimple RJ
Mol Interv; 2010 Dec; 10(6):341-53. PubMed ID: 21263160
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
17.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
18. Additional hepatic
Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 Trial of
Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
Hubble D; Kong G; Michael M; Johnson V; Ramdave S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1869-75. PubMed ID: 20445977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]